CERo Therapeutics says AML patient in CER-1236 Phase 1 trial proceeds to allogeneic stem cell transplant

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Holdings, Inc. - Common Stock

CERO

0.00
  • Cero Therapeutics reported a Phase 1 CERTAIN-T update for its CER-1236 cell therapy in blood cancers; results were previously presented in February.
  • Investigators described clinical improvement in some treated patients, including one AML patient who proceeded to an allogeneic stem cell transplant.
  • Safety to date remained consistent with earlier disclosures, with no severe treatment-related events reported during the key early monitoring window.
  • Six patients have been treated so far; the study has moved into its third planned cohort as dose escalation continues.
  • The next cohort targets a higher planned dose and broadens screening to additional myeloid diseases, including MDS and myelofibrosis.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606150815PRIMZONEFULLFEED9745737) on June 15, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.